Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Net Cash Flow: 2016-2025

Historic Net Cash Flow for Summit Therapeutics (SMMT) over the last 9 years, with Sep 2025 value amounting to -$59.3 million.

  • Summit Therapeutics' Net Cash Flow fell 190.97% to -$59.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.8 million, marking a year-over-year increase of 106.97%. This contributed to the annual value of $33.8 million for FY2024, which is 105.84% up from last year.
  • Summit Therapeutics' Net Cash Flow amounted to -$59.3 million in Q3 2025, which was down 168.77% from $86.3 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Net Cash Flow high stood at $525.3 million for Q4 2022, and its period low was -$578.1 million during Q1 2023.
  • For the 3-year period, Summit Therapeutics' Net Cash Flow averaged around -$37.3 million, with its median value being -$9.8 million (2024).
  • Per our database at Business Quant, Summit Therapeutics' Net Cash Flow spiked by 6,634.72% in 2022 and then tumbled by 10,024.15% in 2023.
  • Quarterly analysis of 5 years shows Summit Therapeutics' Net Cash Flow stood at -$8.0 million in 2021, then skyrocketed by 6,634.72% to $525.3 million in 2022, then plummeted by 90.98% to $47.4 million in 2023, then crashed by 76.36% to $11.2 million in 2024, then crashed by 190.97% to -$59.3 million in 2025.
  • Its last three reported values are -$59.3 million in Q3 2025, $86.3 million for Q2 2025, and $106.6 million during Q1 2025.